Literature DB >> 32198310

Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders.

Daniela D Maltais1, Lennon G Jordan1, Hoon-Ki Min1, Toji Miyagawa2, Scott A Przybelski3, Timothy G Lesnick3, Robert R Reichard4, Dennis W Dickson5, Melissa E Murray5, Kejal Kantarci1, Bradley F Boeve2, Val J Lowe6.   

Abstract

Our rationale was to conduct a retrospective study comparing 3 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) SPECT quantitative methods in patients with neurodegenerative syndromes as referenced to neuropathologic findings.
Methods: 123I-FP-CIT-SPECT and neuropathologic findings among patients with neurodegenerative syndromes from the Mayo Alzheimer Disease Research Center and Mayo Clinic Study of Aging were examined. Three 123I-FP-CIT SPECT quantitative assessment methods-MIMneuro, DaTQUANT, and manual region-of-interest creation on a workstation-were compared with neuropathologic findings describing the presence or absence of Lewy body disease (LBD). Striatum-to-background ratios (SBRs) generated by DaTQUANT were compared with the calculated SBRs of the manual method and MIMneuro. The left and right SBRs for caudate, putamen, and striatum were evaluated with the manual method. For DaTQUANT and MIMneuro, the left, right, total, and average SBRs and z scores for whole striatum, caudate, putamen, anterior putamen, and posterior putamen were calculated.
Results: The cohort included 24 patients (20 [83%] male, mean age for all patients at death, 75.4 ± 10.0 y). The antemortem clinical diagnoses were Alzheimer disease dementia (n = 6), probable dementia with Lewy bodies (n = 12), mixed Alzheimer disease dementia and probable dementia with Lewy bodies (n = 1), Parkinson disease with mild cognitive impairment (n = 2), corticobasal syndrome (n = 1), idiopathic rapid-eye-movement sleep behavior disorder (n = 1), and behavioral-variant frontotemporal dementia (n = 1). Seventeen (71%) had LBD. All 3 123I-FP-CIT SPECT quantitative methods had an area under the receiver-operating-characteristics curve ranging from more than 0.93 to up to 1.000 (P < 0.001) and showed excellent discrimination between LBD and non-LBD patients in each region assessed (P < 0.001). There was no significant difference between the accuracy of the regions in discriminating the 2 groups, with good discrimination for both caudate and putamen.
Conclusion: All 3 123I-FP-CIT SPECT quantitative methods showed excellent discrimination between LBD and non-LBD patients in each region assessed, using both SBRs and z scores.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  123I-FP-CIT SPECT; 123I-ioflupane; Lewy body disease; dementia with Lewy bodies; neuropathology

Mesh:

Substances:

Year:  2020        PMID: 32198310      PMCID: PMC9364894          DOI: 10.2967/jnumed.119.239418

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   11.082


  38 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow.

Authors:  Bich-Ngoc-Thanh Tang; Satoshi Minoshima; Jean George; Annie Robert; Christian Swine; Patrice Laloux; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

Review 3.  SPECT imaging evaluation in movement disorders: far beyond visual assessment.

Authors:  Kosmas Badiavas; Elisavet Molyvda; Ioannis Iakovou; Magdalini Tsolaki; Kyriakos Psarrakos; Nikolaos Karatzas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-02       Impact factor: 9.236

4.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

5.  Diagnostic utility of letter fluency, category fluency, and fluency difference scores in Alzheimer's disease.

Authors:  Jane H Cerhan; Robert J Ivnik; Glenn E Smith; Eric C Tangalos; Ronald C Petersen; Bradley F Boeve
Journal:  Clin Neuropsychol       Date:  2002-02       Impact factor: 3.535

6.  EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.

Authors:  Jacques Darcourt; Jan Booij; Klaus Tatsch; Andrea Varrone; Thierry Vander Borght; Ozlem L Kapucu; Kjell Någren; Flavio Nobili; Zuzana Walker; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

Review 7.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 8.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

9.  Attenuation and scatter correction in I-123 FP-CIT SPECT do not affect the clinical diagnosis of dopaminergic system neurodegeneration.

Authors:  Miho Akahoshi; Koichiro Abe; Yumiko Uchiyama; Mitsuru Momose; Kenji Fukushima; Kazuo Kitagawa; Shuji Sakai
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

10.  Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.

Authors:  Alan J Thomas; Johannes Attems; Sean J Colloby; John T O'Brien; Ian McKeith; Rodney Walker; Lean Lee; David Burn; Debra J Lett; Zuzana Walker
Journal:  Neurology       Date:  2016-12-09       Impact factor: 9.910

View more
  5 in total

1.  Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech.

Authors:  Zeynep Idil Seckin; Jennifer L Whitwell; Rene L Utianski; Hugo Botha; Farwa Ali; Joseph R Duffy; Heather M Clark; Mary M Machulda; Lennon G Jordan; Hoon-Ki Min; Val J Lowe; Keith A Josephs
Journal:  J Neurol       Date:  2020-05-09       Impact factor: 4.849

2.  The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia.

Authors:  Toji Miyagawa; Scott A Przybelski; Daniela Maltais; Hoon-Ki Min; Lennon Jordan; Timothy G Lesnick; Qin Chen; Jonathan Graff-Radford; David Jones; Rodolfo Savica; David Knopman; Ronald Petersen; Walter K Kremers; Leah K Forsberg; Julie A Fields; Tanis J Ferman; Laura Allen; Joseph Parisi; R Ross Reichard; Melissa Murray; Dennis Dickson; Bradley F Boeve; Kejal Kantarci; Val J Lowe
Journal:  Neurobiol Aging       Date:  2020-12-15       Impact factor: 4.673

3.  Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography.

Authors:  Elijah Mak; Nicolas Nicastro; Maura Malpetti; George Savulich; Ajenthan Surendranathan; Negin Holland; Luca Passamonti; P Simon Jones; Stephen F Carter; Li Su; Young T Hong; Tim D Fryer; Guy B Williams; Franklin Aigbirhio; James B Rowe; John T O'Brien
Journal:  Neurobiol Aging       Date:  2020-11-14       Impact factor: 4.673

4.  β-Amyloid PET and 123I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia.

Authors:  Qin Chen; Val J Lowe; Bradley F Boeve; Scott A Przybelski; Toji Miyagawa; Matthew L Senjem; Clifford R Jack; Timothy G Lesnick; Walter K Kremers; Julie A Fields; Hoon-Ki Min; Christopher G Schwarz; Jeffrey L Gunter; Jonathan Graff-Radford; Rodolfo Savica; David S Knopman; David Jones; Tanis J Ferman; Neill R Graff-Radford; Ronald C Petersen; Kejal Kantarci
Journal:  Neurology       Date:  2021-01-06       Impact factor: 9.910

Review 5.  Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.

Authors:  Ruiqing Ni; Roger M Nitsch
Journal:  Front Aging Neurosci       Date:  2022-01-03       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.